Generally, therapies focusing on translocating targets, such as HuR, and its targeting mRNAs, such as WEE1, could turn out to be more efficient therapeutic strategies than the targeting of PDA cells’ genetic alterations [32]. Here, WEE1 is linked to Patent ductus arteriosus.